MicroRNA-663  ||| S:0 E:13 ||| NNP
inhibits  ||| S:13 E:22 ||| VBD
the  ||| S:22 E:26 ||| DT
proliferation ||| S:26 E:39 ||| NN
,  ||| S:39 E:41 ||| ,
migration  ||| S:41 E:51 ||| NN
and  ||| S:51 E:55 ||| CC
invasion  ||| S:55 E:64 ||| NN
of  ||| S:64 E:67 ||| IN
glioblastoma  ||| S:67 E:80 ||| JJ
cells  ||| S:80 E:86 ||| NNS
via  ||| S:86 E:90 ||| IN
targeting  ||| S:90 E:100 ||| VBG
TGF-β1  ||| S:100 E:107 ||| NNP
Cell  ||| S:107 E:112 ||| NNP
migration  ||| S:112 E:122 ||| NN
and  ||| S:122 E:126 ||| CC
invasion  ||| S:126 E:135 ||| NNS
are  ||| S:135 E:139 ||| VBP
key  ||| S:139 E:143 ||| JJ
processes  ||| S:143 E:153 ||| NNS
involved  ||| S:153 E:162 ||| VBN
during  ||| S:162 E:169 ||| IN
tumor  ||| S:169 E:175 ||| NN
metastasis ||| S:175 E:185 ||| NN
.  ||| S:185 E:187 ||| .
Recently ||| S:187 E:195 ||| RB
,  ||| S:195 E:197 ||| ,
microRNAs  ||| S:197 E:207 ||| NNP
( ||| S:207 E:208 ||| -LRB-
miRs ||| S:208 E:212 ||| NNP
)  ||| S:212 E:214 ||| -RRB-
have  ||| S:214 E:219 ||| VBP
been  ||| S:219 E:224 ||| VBN
demonstrated  ||| S:224 E:237 ||| VBN
to  ||| S:237 E:240 ||| TO
play  ||| S:240 E:245 ||| VB
important  ||| S:245 E:255 ||| JJ
roles  ||| S:255 E:261 ||| NNS
in  ||| S:261 E:264 ||| IN
the  ||| S:264 E:268 ||| DT
regulation  ||| S:268 E:279 ||| NN
of  ||| S:279 E:282 ||| IN
cancer  ||| S:282 E:289 ||| NN
metastasis ||| S:289 E:299 ||| NN
.  ||| S:299 E:301 ||| .
However ||| S:301 E:308 ||| RB
,  ||| S:308 E:310 ||| ,
the  ||| S:310 E:314 ||| DT
underlying  ||| S:314 E:325 ||| JJ
mechanisms  ||| S:325 E:336 ||| NNS
remain  ||| S:336 E:343 ||| VBP
unknown ||| S:343 E:350 ||| JJ
.  ||| S:350 E:352 ||| .
Here ||| S:352 E:356 ||| RB
,  ||| S:356 E:358 ||| ,
we  ||| S:358 E:361 ||| PRP
aimed  ||| S:361 E:367 ||| VBD
to  ||| S:367 E:370 ||| TO
investigate  ||| S:370 E:382 ||| VB
the  ||| S:382 E:386 ||| DT
exact  ||| S:386 E:392 ||| JJ
role  ||| S:392 E:397 ||| NN
of  ||| S:397 E:400 ||| IN
miR-663  ||| S:400 E:408 ||| CD
in  ||| S:408 E:411 ||| IN
the  ||| S:411 E:415 ||| DT
metastasis  ||| S:415 E:426 ||| NN
of  ||| S:426 E:429 ||| IN
glioblastoma  ||| S:429 E:442 ||| NN
as  ||| S:442 E:445 ||| IN
well  ||| S:445 E:450 ||| RB
as  ||| S:450 E:453 ||| IN
the  ||| S:453 E:457 ||| DT
underlying  ||| S:457 E:468 ||| JJ
mechanisms ||| S:468 E:478 ||| NNS
.  ||| S:478 E:480 ||| .
By  ||| S:480 E:483 ||| IN
performing  ||| S:483 E:494 ||| VBG
quantitative  ||| S:494 E:507 ||| JJ
reverse  ||| S:507 E:515 ||| JJ
transcription-polymerase  ||| S:515 E:540 ||| JJ
chain  ||| S:540 E:546 ||| NN
reaction  ||| S:546 E:555 ||| NN
( ||| S:555 E:556 ||| -LRB-
RT-PCR ||| S:556 E:562 ||| NNP
)  ||| S:562 E:564 ||| -RRB-
analysis ||| S:564 E:572 ||| NN
,  ||| S:572 E:574 ||| ,
we  ||| S:574 E:577 ||| PRP
demonstrated  ||| S:577 E:590 ||| VBD
that  ||| S:590 E:595 ||| IN
miR-663  ||| S:595 E:603 ||| NNP
was  ||| S:603 E:607 ||| VBD
significantly  ||| S:607 E:621 ||| RB
downregulated  ||| S:621 E:635 ||| VBN
in  ||| S:635 E:638 ||| IN
glioblastoma  ||| S:638 E:651 ||| JJ
tissues  ||| S:651 E:659 ||| NNS
( ||| S:659 E:660 ||| -LRB-
n=25 ||| S:660 E:664 ||| NNP
) ||| S:664 E:665 ||| -RRB-
,  ||| S:665 E:667 ||| ,
when  ||| S:667 E:672 ||| WRB
compared  ||| S:672 E:681 ||| VBN
to  ||| S:681 E:684 ||| TO
that  ||| S:684 E:689 ||| DT
in  ||| S:689 E:692 ||| IN
normal  ||| S:692 E:699 ||| JJ
brain  ||| S:699 E:705 ||| NN
tissues  ||| S:705 E:713 ||| NNS
( ||| S:713 E:714 ||| -LRB-
n=15 ||| S:714 E:718 ||| NNP
) ||| S:718 E:719 ||| -RRB-
.  ||| S:719 E:721 ||| .
In  ||| S:721 E:724 ||| IN
addition ||| S:724 E:732 ||| NN
,  ||| S:732 E:734 ||| ,
its  ||| S:734 E:738 ||| PRP$
expression  ||| S:738 E:749 ||| NN
levels  ||| S:749 E:756 ||| NNS
were  ||| S:756 E:761 ||| VBD
also  ||| S:761 E:766 ||| RB
reduced  ||| S:766 E:774 ||| VBN
in  ||| S:774 E:777 ||| IN
human  ||| S:777 E:783 ||| JJ
glioblastoma  ||| S:783 E:796 ||| JJ
cell  ||| S:796 E:801 ||| NN
lines ||| S:801 E:806 ||| NNS
,  ||| S:806 E:808 ||| ,
A172  ||| S:808 E:813 ||| NNP
and  ||| S:813 E:817 ||| CC
U87 ||| S:817 E:820 ||| NNP
.  ||| S:820 E:822 ||| .
Furthermore ||| S:822 E:833 ||| RB
,  ||| S:833 E:835 ||| ,
restoration  ||| S:835 E:847 ||| NN
of  ||| S:847 E:850 ||| IN
miR-663  ||| S:850 E:858 ||| CD
expression  ||| S:858 E:869 ||| NN
led  ||| S:869 E:873 ||| VBD
to  ||| S:873 E:876 ||| TO
a  ||| S:876 E:878 ||| DT
significant  ||| S:878 E:890 ||| JJ
decrease  ||| S:890 E:899 ||| NN
in  ||| S:899 E:902 ||| IN
the  ||| S:902 E:906 ||| DT
cell  ||| S:906 E:911 ||| NN
proliferation ||| S:911 E:924 ||| NN
,  ||| S:924 E:926 ||| ,
migration  ||| S:926 E:936 ||| NN
and  ||| S:936 E:940 ||| CC
invasion  ||| S:940 E:949 ||| NN
of  ||| S:949 E:952 ||| IN
human  ||| S:952 E:958 ||| JJ
glioblastoma  ||| S:958 E:971 ||| JJ
A172  ||| S:971 E:976 ||| NN
and  ||| S:976 E:980 ||| CC
U87  ||| S:980 E:984 ||| CD
cells ||| S:984 E:989 ||| NNS
.  ||| S:989 E:991 ||| .
We  ||| S:991 E:994 ||| PRP
further  ||| S:994 E:1002 ||| RB
identified  ||| S:1002 E:1013 ||| VBN
TGF-β1  ||| S:1013 E:1020 ||| CD
as  ||| S:1020 E:1023 ||| IN
a  ||| S:1023 E:1025 ||| DT
direct  ||| S:1025 E:1032 ||| JJ
target  ||| S:1032 E:1039 ||| NN
of  ||| S:1039 E:1042 ||| IN
miR-663 ||| S:1042 E:1049 ||| NNP
,  ||| S:1049 E:1051 ||| ,
and  ||| S:1051 E:1055 ||| CC
found  ||| S:1055 E:1061 ||| VBD
that  ||| S:1061 E:1066 ||| IN
the  ||| S:1066 E:1070 ||| DT
expression  ||| S:1070 E:1081 ||| NN
of  ||| S:1081 E:1084 ||| IN
TGF-β1  ||| S:1084 E:1091 ||| NNP
was  ||| S:1091 E:1095 ||| VBD
negatively  ||| S:1095 E:1106 ||| RB
mediated  ||| S:1106 E:1115 ||| VBN
by  ||| S:1115 E:1118 ||| IN
miR-663  ||| S:1118 E:1126 ||| CD
at  ||| S:1126 E:1129 ||| IN
the  ||| S:1129 E:1133 ||| DT
post-transcriptional  ||| S:1133 E:1154 ||| JJ
level  ||| S:1154 E:1160 ||| NN
in  ||| S:1160 E:1163 ||| IN
glioblastoma  ||| S:1163 E:1176 ||| JJ
cells ||| S:1176 E:1181 ||| NNS
.  ||| S:1181 E:1183 ||| .
Moreover ||| S:1183 E:1191 ||| RB
,  ||| S:1191 E:1193 ||| ,
overexpression  ||| S:1193 E:1208 ||| VBG
of  ||| S:1208 E:1211 ||| IN
TGF-β1  ||| S:1211 E:1218 ||| NNP
significantly  ||| S:1218 E:1232 ||| RB
reversed  ||| S:1232 E:1241 ||| VBD
the  ||| S:1241 E:1245 ||| DT
inhibitory  ||| S:1245 E:1256 ||| JJ
effects  ||| S:1256 E:1264 ||| NNS
of  ||| S:1264 E:1267 ||| IN
miR-663  ||| S:1267 E:1275 ||| CD
upregulation  ||| S:1275 E:1288 ||| NN
on  ||| S:1288 E:1291 ||| IN
the  ||| S:1291 E:1295 ||| DT
proliferation ||| S:1295 E:1308 ||| NN
,  ||| S:1308 E:1310 ||| ,
migration  ||| S:1310 E:1320 ||| NN
and  ||| S:1320 E:1324 ||| CC
invasion  ||| S:1324 E:1333 ||| NN
in  ||| S:1333 E:1336 ||| IN
A172  ||| S:1336 E:1341 ||| NNP
and  ||| S:1341 E:1345 ||| CC
U87  ||| S:1345 E:1349 ||| CD
cells ||| S:1349 E:1354 ||| NNS
.  ||| S:1354 E:1356 ||| .
In  ||| S:1356 E:1359 ||| IN
addition ||| S:1359 E:1367 ||| NN
,  ||| S:1367 E:1369 ||| ,
our  ||| S:1369 E:1373 ||| PRP$
data  ||| S:1373 E:1378 ||| NNS
suggest  ||| S:1378 E:1386 ||| VBP
that  ||| S:1386 E:1391 ||| IN
MMP2  ||| S:1391 E:1396 ||| NNP
and  ||| S:1396 E:1400 ||| CC
E-cadherin ||| S:1400 E:1410 ||| JJ
,  ||| S:1410 E:1412 ||| ,
a  ||| S:1412 E:1414 ||| DT
key  ||| S:1414 E:1418 ||| JJ
factor  ||| S:1418 E:1425 ||| NN
in  ||| S:1425 E:1428 ||| IN
epithelial-mesenchymal  ||| S:1428 E:1451 ||| JJ
transition  ||| S:1451 E:1462 ||| NN
( ||| S:1462 E:1463 ||| -LRB-
EMT ||| S:1463 E:1466 ||| NNP
) ||| S:1466 E:1467 ||| -RRB-
,  ||| S:1467 E:1469 ||| ,
are  ||| S:1469 E:1473 ||| VBP
involved  ||| S:1473 E:1482 ||| VBN
in  ||| S:1482 E:1485 ||| IN
the  ||| S:1485 E:1489 ||| DT
miR-633 ||| S:1489 E:1496 ||| CD
/ ||| S:1496 E:1497 ||| CD
TGF-β1-mediated  ||| S:1497 E:1513 ||| CD
metastasis  ||| S:1513 E:1524 ||| NN
of  ||| S:1524 E:1527 ||| IN
glioblastoma ||| S:1527 E:1539 ||| NN
.  ||| S:1539 E:1541 ||| .
In  ||| S:1541 E:1544 ||| IN
summary ||| S:1544 E:1551 ||| NN
,  ||| S:1551 E:1553 ||| ,
miR-663  ||| S:1553 E:1561 ||| NNP
plays  ||| S:1561 E:1567 ||| VBZ
an  ||| S:1567 E:1570 ||| DT
inhibitory  ||| S:1570 E:1581 ||| JJ
role  ||| S:1581 E:1586 ||| NN
in  ||| S:1586 E:1589 ||| IN
the  ||| S:1589 E:1593 ||| DT
regulation  ||| S:1593 E:1604 ||| NN
of  ||| S:1604 E:1607 ||| IN
proliferation ||| S:1607 E:1620 ||| NN
,  ||| S:1620 E:1622 ||| ,
migration  ||| S:1622 E:1632 ||| NN
and  ||| S:1632 E:1636 ||| CC
invasion  ||| S:1636 E:1645 ||| NN
of  ||| S:1645 E:1648 ||| IN
glioblastoma  ||| S:1648 E:1661 ||| JJ
cells ||| S:1661 E:1666 ||| NNS
,  ||| S:1666 E:1668 ||| ,
partly  ||| S:1668 E:1675 ||| RB
at  ||| S:1675 E:1678 ||| IN
least ||| S:1678 E:1683 ||| JJS
,  ||| S:1683 E:1685 ||| ,
via  ||| S:1685 E:1689 ||| IN
direct  ||| S:1689 E:1696 ||| JJ
mediation  ||| S:1696 E:1706 ||| NN
of  ||| S:1706 E:1709 ||| IN
TGF-β1  ||| S:1709 E:1716 ||| CD
as  ||| S:1716 E:1719 ||| IN
well  ||| S:1719 E:1724 ||| RB
as  ||| S:1724 E:1727 ||| IN
downstream  ||| S:1727 E:1738 ||| JJ
MMP2  ||| S:1738 E:1743 ||| NN
and  ||| S:1743 E:1747 ||| CC
E-cadherin ||| S:1747 E:1757 ||| JJ
.  ||| S:1757 E:1759 ||| .
Therefore ||| S:1759 E:1768 ||| RB
,  ||| S:1768 E:1770 ||| ,
we  ||| S:1770 E:1773 ||| PRP
suggest  ||| S:1773 E:1781 ||| VBP
that  ||| S:1781 E:1786 ||| IN
miR-663  ||| S:1786 E:1794 ||| NNP
is  ||| S:1794 E:1797 ||| VBZ
a  ||| S:1797 E:1799 ||| DT
potential  ||| S:1799 E:1809 ||| JJ
candidate  ||| S:1809 E:1819 ||| NN
for  ||| S:1819 E:1823 ||| IN
the  ||| S:1823 E:1827 ||| DT
prevention  ||| S:1827 E:1838 ||| NN
of  ||| S:1838 E:1841 ||| IN
glioblastoma  ||| S:1841 E:1854 ||| JJ
metastasis ||| S:1854 E:1864 ||| NN
.  ||| S:1864 E:1866 ||| .
